This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Caron, P. Articles by Sassano, P. Search for Related Content PubMed PubMed Citation Articles by Caron, P. Articles by Sassano, P.

Efficacy of the Long-Acting Octreotide Formulation (Octreotide-Lar) in Patients with Thyrotropin-Secreting Pituitary Adenomas

Department of Endocrinology, University Hospital (P.Ca.), 31403 Toulouse; Department of Endocrinology, University Hospital (S.A.), 80054 Amiens; Department of Endocrinology, University Hospital (C.B.), 59037 Lille; Department of Endocrinology, University Hospital (P.Ch.), 94276 Paris; Department of Endocrinology, University Hospital (J.M.K.), 76233 Rouen; Department of Endocrinology, University Hospital (M.P.), 69321 Lyon; Department of Endocrinology, University Hospital (R.M.)., 86021 Poitiers; Department of Endocrinology, University Hospital (C.T.), 63003 Clermont-Ferrand; Department of Endocrinology, University Hospital (E.V.), 87042 Limoges; and Novartis Pharma SA (P.S.), 92506 Rueil Malmaison, France

Address all correspondence and requests for reprints to: Philippe Caron, M.D., Service d’Endocrinologie et Maladies Métaboliques, University Hospital Rangueil, 1 avenue J. Poulhés, 31403 Toulouse Cedex, France. E-mail: caron.p{at}chu-toulouse.fr

Abstract

The presence of somatostatin receptors on TSH-secreting pituitary adenomas allows treatment of central hyperthyroidism with somatostatin analogs. Six women and 5 men (mean ± SEM age, 43 ± 3 yr) presented TSH-secreting pituitary adenomas (micro, n = 2; macro, n = 9). Seven patients had previously been treated with partial surgical removal (n = 6) and/or external radiation (n = 4) of their adenoma at least 1 yr before the study, whereas 4 patients had not been treated before somatostatin analog therapy. TSH, free T₄, and free T₃ levels were in the normal range during treatment with sc injections (n = 9) or continuous infusion (n = 2) of octreotide (280 ± 25 µg/day). Mean thyroid hormone levels increased (P < 0.01) after the washout period (34 ± 6 days). The patients received monthly im injections of 20 mg Octreotide-LAR. In patients with an elevated free T₄ level after 3 months (n = 1) the Octreotide-LAR dose was increased to 30 mg. After 3 months of Octreotide-LAR treatment, TSH, free T₄/T₃, and -subunit levels decreased, and 10 patients were euthyroid with normal free T₄ levels. These results remained at the same level over the next 3 months. There were no statistically significant differences in the TSH and free T₄ responses to sc octreotide or im Octreotide-LAR between previously untreated patients and patients who had undergone surgical resection and/or pituitary radiation before somatostatin analog treatment. During Octreotide-LAR treatment, minor digestive problems or moderate discomfort at the injection site, lasting less than 48 h, were reported in 6 and 5 patients, respectively. Gallbladder echographies did not reveal new gallstones during Octreotide-LAR treatment. In conclusion, this study shows that monthly im Octreotide-LAR is as effective as daily sc octreotide in controlling hyperthyroidism in patients with TSH-secreting pituitary adenomas, in both previously untreated patients and patients treated with surgery and/or pituitary radiotherapy. Octreotide-LAR is well tolerated, except for minor digestive problems or mild pain at the injection site. Therefore, Octreotide-LAR appears to be a useful therapeutic tool to facilitate medical treatment of TSH-secreting pituitary adenomas in patients who need long-term somatostatin analog therapy.

This article has been cited by other articles:

				C Daousi, P. M Foy, and I. A Macfarlane Ablative thyroid treatment for thyrotoxicosis due to thyrotropin-producing pituitary tumours BMJ Case Reports, January 22, 2009; 2009(jan21_1): bcr0720080541 - bcr0720080541. [Abstract] [Full Text]

				C Daousi, P M Foy, and I A MacFarlane Ablative thyroid treatment for thyrotoxicosis due to thyrotropin-producing pituitary tumours J. Neurol. Neurosurg. Psychiatry, January 1, 2007; 78(1): 93 - 95. [Abstract] [Full Text] [PDF]

				C Susini and L Buscail Rationale for the use of somatostatin analogs as antitumor agents Ann. Onc., December 1, 2006; 17(12): 1733 - 1742. [Abstract] [Full Text] [PDF]

				E. C. Nemergut, A. S. Dumont, U. T. Barry, and E. R. Laws Perioperative Management of Patients Undergoing Transsphenoidal Pituitary Surgery Anesth. Analg., October 1, 2005; 101(4): 1170 - 1181. [Abstract] [Full Text] [PDF]